CT medium circulates in blood pool

Article

Photogen Technologies is testing a contrast agent that stays in the vascular system for at least 20 minutes with little diffusion outside. If tests pan out, the experimental agent, which has been tested only in animals, could serve as both a perfusion

Photogen Technologies is testing a contrast agent that stays in the vascular system for at least 20 minutes with little diffusion outside. If tests pan out, the experimental agent, which has been tested only in animals, could serve as both a perfusion and blood pool agent. Preclinical studies indicate that the proprietary agent, called PH-50, has potential in coronary, cardiac, great vessel, and renal arterial CT. Through luminaries at Stanford University, the New Hope, PA, company also hopes to explore the use of this agent as a means for imaging soft noncalcified plaques in coronary arteries, where its presence is a marker of likelihood to rupture and cause sudden death.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.